Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
336
resultados
Última actualización
28/08/2026 [07:35:00]
Resultados 25 a 50 de 336
Resumen de: WO2025076635A1
Described herein are anti-alpha-synuclein antibodies. More specifically, described herein are antibodies specific to serine 129 phosphorylated alpha-synuclein. Further described herein is the use of the anti alpha-synuclein antibodies for the treatment or diagnosis of a synucleinopathy. Further described are kits and compositions comprising the anti alpha-synuclein antibodies detecting alpha-synuclein in a sample.
Resumen de: WO2025080894A1
In one aspect, the present disclosure provides a method of detecting a presence or absence of a biomarker for a disease in the sample, wherein the biomarker comprises: a) a complex of physiologically active target macromolecules or a fragment or portion thereof and target macromolecules that are not physiologically active; b) a conformation of the physiologically active macromolecules or fragment thereof when the physiologically active target macromolecules or the fragment or portion thereof is a complex with a non- physiologically active target macromolecule; c) the conformation of physiologically active target macromolecules or a portion or fragment thereof in a PAT-Tau complex; d) the conformation of non-physiologically active target macromolecules or a portion or fragment thereof in a PAT-Tau complex; or e) a combination of a), b), c), d) and/or e).
Resumen de: WO2021089651A1
The current application relates to personalised nutrition methods, particularly to methods of determining whether a human subject would benefit from taking a urolithin supplement and methods for determining the treatment dose of a urolithin supplement for a human subject. Particularly methods comprising determining the level of urolithin or a urolithin conjugate in a biological fluid, such as a dried whole blood spot sample, a dried plasma spot, a m spot sample or a urine sample The current application also relates to systems for presenting whether a human subject would benefit from taking a urolithin supplement and for presenting the treatment dose of a urolithin supplement for a human subject. The current application also relates to computer implementation of methods of the invention.
Resumen de: JP2026132804A
0001 【課題】神経変性疾患の診断を補助する方法、およびアルツハイマー型認知症とパーキンソン病の鑑別を補助する方法；神経変性疾患の診断キット、およびアルツハイマー型認知症とパーキンソン病の鑑別キット；並びに神経変性疾患の診断用バイオマーカー、神経変性疾患の診断用バイオマーカーセット、およびアルツハイマー型認知症とパーキンソン病の鑑別用バイオマーカーセットを提供すること。 【解決手段】被検試料中の、細胞外小胞におけるＣＤ４１の量またはＣＤ６１の量を検出することを含む神経変性疾患の診断を補助する方法であって、上記ＣＤ４１の量またはＣＤ６１の量を含む指標が、神経変性疾患以外の対象よりも低いことが、神経変性疾患を示唆する、神経変性疾患の診断を補助する方法。 【選択図】なし
Resumen de: WO2021195768A1
An aqueous stabilizing composition for preserving a bodily fluid at ambient temperature is provided. The aqueous stabilizing composition comprises: a sugar selected from a monosaccharide, a disaccharide, or a combination thereof; a buffering agent; a C1-C6 alkanol; boric acid, a salt of boric acid, or a combination thereof; and a chelating agent; wherein the composition has a pH of from 4.5 to 5.2. A method for preserving a bodily fluid using the aqueous stabilizing composition is also provided, the method comprising: a) obtaining a sample of the bodily fluid; b) contacting the bodily fluid with the aqueous stabilizing composition to form a mixture; c) mixing the mixture of (b) to form a homogeneous mixture; and d) storing the homogeneous mixture at ambient temperature.
Resumen de: US20260235629A1
0000 Disclosed are methods, compositions, and computer-implemented systems for diagnosing, staging, and monitoring neurological and neurovascular disorders, including Alzheimer's disease, vascular dementia, traumatic brain and spinal-cord injury, stroke, demyelinating disease, and central nervous system vasculitis. The invention involves measuring levels of endothelial and blood-brain-barrier-associated biomarkers—comprising claudins 1-34 (including claudin-14 and claudin-23), endothelins (ET-1 to ET-3), ESAM, ESM1 (Endocan), neuropilins (NRP1 and NRP2), ZIC1, FOXP2, and neuroligins (NLGN 1-4 and subtypes)—in biological samples such as cerebrospinal fluid, plasma, serum, or other biofluids. Altered biomarker patterns indicate endothelial activation, barrier dysfunction, or neurovascular signaling imbalance associated with disease progression or therapeutic response. Also provided are analytical kits containing capture reagents, calibration standards, and a non-transitory computer-readable medium configured to integrate biomarker data, as well as machine-learning models trained to generate diagnostic, prognostic, or vascular-safety indices supporting individualized management of neurodegenerative and neurovascular conditions.
Resumen de: US20260235626A1
The present invention relates to biomarker-based analyses for the stratification of Huntington Disease (HD) in a subject. The invention further relates to protein biomarkers (and particular combinations) and their use in monitoring biochemical changes in HD patients indicative of the stage, severity, progression, or age-of-onset of disease; guidance for the design of clinical trials; for selecting a therapeutic regimen and monitoring response to treatment. The invention further comprises methods for the detection of HD biomarkers in cerebrospinal fluid (CSF) and other biofluids in patients with HD or at risk of developing HD.
Resumen de: US20260234229A1
Disclosed herein are antibodies or antigen-binding fragments thereof and compositions comprising the same. Also disclosed are methods of detecting TAR DNA-binding protein 43 (TDP-43) in a biological sample, diagnosing a neurodegenerative disease in a subject, and selecting whether to enroll a subject in a clinical trial for frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP) using the antibodies or antigen-binding fragments thereof described herein. In addition, disclosed herein are immunoassay kits for selectively detecting TDP-43 in a biological sample.
Resumen de: WO2026167161A1
The present invention relates to biomarkers of cerebrospinal fluid (CSF) flow, methods for determining the synthesis rate and clearance rate of biomolecules in CSF of a subject, methods for determining abnormal CSF flow in a subject and diagnosing and treating disorders associated with abnormal CSF flow.
Resumen de: WO2026169642A2
The disclosure relates to methods of treating stroke, dosing regimens of GDF11, and post-stroke treatment with GDF11.
Resumen de: WO2026170050A1
In one aspect, the present invention provides nucleic acids encoding T cell receptor alpha and beta chains which can associate with each other in order to form functional T cell receptors (TCRs) specific for cryptic epitopes of, for example, HDGFL2 protein, IgLON5 protein and others expressed by a target cell. In other aspects, the invention provides T cell receptors (TCRs) specific for cryptic epitopes, modified T cells expressing the T cell receptors, methods for generating the modified T cells, and diagnostic/screening methods for identifying subjects expressing TCRs comprising antigen specificities for cryptic peptides associated with TDP-43 proteinopathies. In further aspects, the invention provides a method for stimulating an immune response, treating a subject with a TDP-43 proteinopathy, such as amyotrophic lateral sclerosis (ALS) or inclusion body myositis (IBM), and detecting a TDP-43 proteinopathy-associated immune signature in a subject.
Resumen de: WO2026169645A1
Embodiments provided herein relate to methods, compositions and uses for treating heart failure with reduced ejection fraction (HFrEF). Some embodiments relate to methods, compositions and uses of a recombinant viral vector encoding a 2a isoform of a sarco(endo)plasmic reticulum calcium ion (Ca2+) ATPase (SERCA2a) protein.
Resumen de: WO2026165666A1
The present disclosure provides a method for treating long CO VID ( e.g., severe long CO VID) or at least one symptom thereof in a subpopulation of subjects displaying a combination of biomarkers namely a blood level of secreted B-cell activating factor and of membrane BAFF in white blood cells higher than a corresponding reference level; and at least one of blood level of precursor- like marginal zone B-cell populations, zonulin, anti-Mi-2 nuclear antigen autoantibodies, anti-SmD autoantibodies, anti-Ul-snRNP-A autoantibodies, anti-RCN2 autoantibodies, lipopolysaccharide-binding protein (LBP), and p-D-glucan higher than a corresponding reference level, and APRIL lower than a corresponding reference level, comprising administering a therapeutically effective amount of a BAFF inhibitor to the subject. It also provides a method of diagnosing a subject as having long CO VID using the combination of biomarkers and a diagnosis kit comprising ligands for the biomarkers.
Resumen de: JP2026130617A
0001 【課題】 本発明は、生体膜小胞についての従来の解析方法では十分に解析できなかった生体膜小胞の機能を詳細に解析することを目的に、生体膜小胞を網羅的に解析することを課題とする。 【解決手段】 本発明は、生体膜小胞についての解析を行う際、分離または精製を行っていない生体膜小胞を解析対象とすることにより、従来法においては解析データを取得できていなかった生体膜小胞を含めすべての生体膜小胞についてのデータを取得し、そのデータを利用して生体膜小胞の網羅的解析を可能にすることを明らかにし、前記課題を解決した。 【選択図】 なし
Resumen de: US20260232812A1
0000 The present disclosure relates to a novel class of bifunctional molecules that are useful in a targeted or selective degradation of a protein.
Resumen de: US20260234206A1
0000 The present invention relates to proteins and protein libraries particularly for use in methods of screening to identify novel binding partners including diagnostic and therapeutic molecules.
Resumen de: US20260235612A1
0000 Compositions and kits for diagnosing and prognosing Alzheimer's Disease (AD) in a human patient include a binding agent such as a monoclonal antibody for a biomarker conjugated to a detectable moiety such as a fluorophore, wherein the biomarker is chosen from CD163, CD91, CD59, MerTK and other phagocytosis-related molecules. Further compositions and kits employ panels of fluorophore-conjugated monoclonal antibodies for biomarkers including scavenger receptors. Methods for determining the relative expression of biomarkers, diagnosing AD, and determining the efficacy of AD therapeutic candidates such as phagocytosis-promoting agents and scavenger receptor agonists also appear.
Resumen de: TW202142690A
The disclosure relates to double stranded ribonucleic acid (dsRNAi) agents and compositions targeting a leucine-rich repeat kinase 2 (LRRK2) gene, as well as methods of inhibiting expression of a LRRK2 gene and methods of treating subjects having a LRRK2-associated disease or disorder, e.g., Parkinson's disease, using such dsRNAi agents and compositions.
Resumen de: US20260232624A1
0000 A method is for modulating tight junction (TJ) integrity in a subject. The method includes (a) assessing TJ integrity in the subject by quantifying at least one biomarker of TJ integrity in the subject; (b) administering to the subject a first composition containing (i) at least one polyphenol, and (ii) a second substance which is not a polyphenol and which upregulates CAMP gene expression in the subject; (c) reassessing TJ integrity in the subject by quantifying at least one biomarker of TJ integrity in the subject; and (d) repeating steps (b) and (c) until the value of said at least one biomarker is within a target range.
Resumen de: US20260235515A1
Identification of molecular species in a sample based unique fluorescent labeling, light dispersion, and image processing. The molecular species identification methods can be used for diagnosing diseases.
Resumen de: US20260234551A1
0000 Provided is a genetically engineered human pluripotent stem cell line in which an insertion sequence including a nucleotide sequence of a fluorescent reporter gene is inserted following a stop codon of the TUBB3 gene, whereby the TUBB3 gene and the fluorescent reporter gene are co-expressed. Genetic manipulation is made to express the fluorescent reporter gene in response to the expression of the TUBB3 gene, a neural cell marker, so that when the cell line is differentiated into neural cells, the fluorescent signal is observed, thereby allowing for monitoring the differentiation process.
Resumen de: US20260231914A1
Described are transgenic rodents that express a brain-derived neurotrophic factor-nano luciferase fusion protein (BD-NF-NLuc) and methods of making the BDNF-NLuc rodents. Also described are methods involving these rodents and/or cell populations derived from these rodents to screen BDNF-modulating molecules.
Resumen de: US20260232845A1
Methods and kits are provided for inhibiting inflammasome activation in cells of a subject or an inflammation-affected eye in a subject by administering to the subject a composition including a nucleotide sequence encoding a membrane independent CD59 protein operably linked to a promoter for expression and secretion of the membrane independent CD59 protein in the cells or the inflammation-affected eye, the composition inhibiting inflammasome activation.
Resumen de: US20260234272A1
Disclosed herein are inhibitors, such as antibodies, and antigen binding portions thereof, that selectively bind complexes of LTBP1-TGFβ1 and/or LTBP3-TGFβ1. The application also provides methods of use of these inhibitors for, for example, inhibiting TGFβ1 activation, and treating subjects suffering from TGFβ1-related disorders, such as fibrotic conditions. Methods of selecting a context-dependent or context-independent isoform-specific TGFβ1 inhibitor for a subject in need thereof are also provided.
Nº publicación: US20260235628A1 13/08/2026
Solicitante:
DIADEM SPA [IT]
Diadem SpA
Resumen de: US20260235628A1
0000 U-p53 peptide P1 is useful in the determination of the rate of progression of Alzheimer's disease (AD). By quantitating the level of U-p53 peptides in a subject's biological sample, the rate of progression of Alzheimer's disease at the pre-clinical and prodromal stages of the disease in a subject can be determined.
BOPI
Sede Electrónica
